Cyclins and breast cancer (original) (raw)

References

  1. B. Henderson, R. Ross, and L. Bernstein (1988). Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award lecture.Cancer Res. 48:246–253.
    PubMed Google Scholar
  2. C. J. Sherr (1994). G1 phase progression: cycling on cue.Cell 79:551–555.
    PubMed Google Scholar
  3. T. Hunter and J. Pines (1994). Cyclins and cancer II: cyclin D and CDK inhibitors come of age.Cell 79:573–582.
    PubMed Google Scholar
  4. V. Baldin, J. Lukas, M. J. Marcote, M. Pagano, and G. Draetta (1993). Cyclin D1 is a nuclear protein required for cell cycle progression in G1.Genes Dev. 7:812–821.
    PubMed Google Scholar
  5. D. E. Quelle, R. A. Ashmun, S. A. Shurtleff, J.-y. Kato, D. Bar-Sagi, M. F. Roussel, and C. J. Sherr (1993). Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.Genes Dev. 7:1559–1571.
    PubMed Google Scholar
  6. D. Resnitzky, M. Gossen, H. Bujard, and S. I. Reed (1994). Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system.Mol. Cell. Biol. 14:1669–1679.
    PubMed Google Scholar
  7. E. A. Musgrove, C. S. L. Lee, M. F. Buckley, and R. L. Sutherland (1994). Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle.Proc. Natl. Acad. Sci. U.S.A. 91:8022–8026.
    PubMed Google Scholar
  8. R. A. Weinberg (1995). The retinoblastoma protein and cell cycle control.Cell 81:323–330.
    PubMed Google Scholar
  9. E. A. Musgrove, B. Sarcevic, and R. L. Sutherland (1995). Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for CDK2 activation and pRB hyperphosphorylation.J. Cell Biochem. (in press).
  10. D. Resnitzky and S. I. Reed (1995). Different roles for cyclins D1 and E in regulation of the G1-to-S transition.Mol. Cell. Biol. 15:3463–3469.
    PubMed Google Scholar
  11. J. Lukas, H. Müller, J. Bartkova, D. Spitkovsky, A. A. Kjerulff, P. Jansen-Dürr, M. Strauss, and J. Bartek (1994). DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1.J. Cell Biol. 125:625–638.
    PubMed Google Scholar
  12. D. O. Morgan (1995). Principles of CDK regulation.Nature 374:131–134.
    PubMed Google Scholar
  13. C. J. Sherr and J. M. Roberts (1995). Inhibitors of mammalian G1 cyclin-dependent kinases.Genes Dev. 9:1149–1163.
    PubMed Google Scholar
  14. O. Aprelikova, Y. Xiong, and E. T. Liu (1995). Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase.J. Biol. Chem. 270:18195–18197.
    PubMed Google Scholar
  15. E. A. Musgrove and R. L. Sutherland (1994). Cell cycle control by steroid hormones. In M. G. Parker (ed.),Seminars in Cancer Biology, Academic Press, London,5:381–389.
    Google Scholar
  16. C. K. W. Watts, N. R. C. Wilcken, J. A. Hamilton, K. J. E. Sweeney, E. A. Musgrove, and R. L. Sutherland (1995). Mechanisms of antiestrogen, progestin/antiprogestin and retinoid inhibition of cell cycle progression in breast cancer cells. In J. P. Pasqualini and B. S. Katzenellenbogen (eds.),Hormone-Dependent Cancers. Molecular and Cellular Endocrinology, Marcel Dekker, New York, pp 119–140.
    Google Scholar
  17. T. Motokura, K. Keyomarsi, H. M. Kronenberg, and A. Arnold (1992). Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the_PRAD_1/cyclin D1 proto-oncogene.J. Biol. Chem. 267:20412–20415.
    PubMed Google Scholar
  18. K. Keyomarsi and A. B. Pardee (1993). Redundant cyclin overexpression and gene amplification in breast cancer cells.Proc. Natl. Acad. Sci. U.S.A. 90:1112–1116.
    PubMed Google Scholar
  19. E. A. Musgrove, J. A. Hamilton, C. S. L. Lee, K. J. E. Sweeney, C. K. W. Watts, and R. L. Sutherland (1993). Growth factor, steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression.Mol. Cell. Biol. 13:3577–3587.
    PubMed Google Scholar
  20. J. Gong, B. Ardelt, F. Traganos, and Z. Darzynkiewicz (1994). Unscheduled expression of cyclin B1 and cyclin E in several leukemic and solid tumor cell lines.Cancer Res. 54:4285–4288.
    PubMed Google Scholar
  21. C. K. W. Watts, K. J. E. Sweeney, A. Warlters, E. A. Musgrove, and R. L. Sutherland (1994). Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells.Breast Cancer Res. Treat. 31:95–105.
    PubMed Google Scholar
  22. C. K. W. Watts, A. Brady, B. Sarcevic, A. deFazio, E. A. Musgrove, and R. L. Sutherland (1995). Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.Mol. Endocrinol. 9:1804–1813.
    PubMed Google Scholar
  23. N. R. C. Wilcken, B. Sarcevic, E. A. Musgrove, and R. L. Sutherland (1995). Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells.Cell Growth Diff. (in press).
  24. L. Xu, D. Sgroi, C. J. Sterner, R. L. Beauchamp, D. M. Pinney, S. Keel, K. Ueki, J. L. Rutter, A. J. Buckler, D. N. Louis, J. F. Gusella, and V. Ramesh (1994). Mutational analysis of_CDKN2_ (MTS1/p16ink4) in human breast carcinomas.Cancer Res. 54:5262–5264.
    PubMed Google Scholar
  25. E. A. Musgrove, R. Lilischkis, A. L. Cornish, C. S. L. Lee, V. Setlur, R. Seshadri, and R. L. Sutherland (1995). Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer.Int. J. Cancer 63:584–591.
    PubMed Google Scholar
  26. J. Bartkova, J. Lukas, H. Müller, D. Lützhøft, M. Strauss, and J. Bartek (1994). Cyclin D1 protein expression and function in human breast cancer.Int. J. Cancer 57:353–361.
    PubMed Google Scholar
  27. O. W. Prall, B. Sarcevic, E. A. Musgrove, C. K. W. Watts, and R. L. Sutherland. Estrogen regulation of cell cycle progression and CDK function in human breast cancer cells. (submitted).
  28. D. Dubik, T. C. Dembinski, and R. P. C. Shiu (1987). Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells.Cancer Res. 47:6517–6521.
    PubMed Google Scholar
  29. J. I. Daksis, R. Y. Lu, L. M. Facchini, W. W. Marhin, and L. J. Z. Penn (1994).Myc induces cyclin D1 expression in the absence of_de novo_ protein synthesis and links mitogen-stimulated signal transduction to the cell cycle.Oncogene 9:3635–3645.
    PubMed Google Scholar
  30. E. A. Musgrove, C. S. L. Lee, and R. L. Sutherland (1991). Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos and c-myc genes.Mol. Cell. Biol. 11:5032–5043.
    PubMed Google Scholar
  31. T. C. Wang, R. D. Cardiff, L. Zukerberg, E. Lees, A. Arnold, and E. V. Schmidt (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice.Nature 369:669–671.
    PubMed Google Scholar
  32. P. Sicinski, J. Liu Donaher, S. B. Parker, T. Li, A. Fazeli, H. Gardner, S. Z. Haslam, R. B. Bronson, S. J. Elledge, and R. A. Weinberg (1995). Cyclin D1 provides a link between development and oncogenesis in the retina and breast.Cell 82:621–630.
    PubMed Google Scholar
  33. C. L. Clarke and R. L. Sutherland (1990). Progestin regulation of cellular proliferation.Endocrinol. Rev. 11:266–302.
    Google Scholar
  34. E. A. Musgrove, C. S. L. Lee, A. L. Cornish, and R. L. Sutherland. Progestin antagonist inhibition of cell cycle progression in T-47D breast cancer cells is preceded by induction of the CDK inhibitor p21. (submitted).
  35. T. K. Said, L. Lou, and D. Medina (1995). Mouse mammary hyperplasias and neoplasias exhibit different patterns of cyclins D1 and D2 binding to Cdk4.Carcinogenesis (in press).
  36. V. Fantl, R. Smith, S. Brookes, C. Dickson, and G. Peters (1993). Chromosome 11q13 abnormalities in human breast cancer.Cancer Surv. 18:77–93.
    PubMed Google Scholar
  37. G. Peters, V. Fantl, R. Smith, S. Brookes, and C. Dickson (1995). Chromosome 11q13 markers and D-type cyclins in breast cancer.Breast Cancer Res. Treat. 33:125–135.
    PubMed Google Scholar
  38. M. F. Buckley, K. J. E. Sweeney, J. A. Hamilton, R. L. Sini, D. L. Manning, R. I. Nicholson, A. deFazio, C. K. W. Watts, E. A. Musgrove, and R. L. Sutherland (1993). Expression and amplification of cyclin genes in human breast cancer.Oncogene 8:2127–2133.
    Google Scholar
  39. C. Gillett, V. Fantl, R. Smith, C. Fisher, J. Bartek, C. Dickson, D. Barnes, and G. Peters (1994). Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.Cancer Res. 54:1812–1817.
    PubMed Google Scholar
  40. J. Bartkova, J. Lukas, M. Strauss, and J. Bartek (1995). Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis.Oncogene 10:775–778.
    PubMed Google Scholar
  41. E. M. J. J. Berns, J. G. M. Klijn, I. L. van Staveren, H. Portengen, E. Noordegraaf, and J. A. Foekens (1992). Prevalence of amplification of the oncogenes c-myc, HER2/neu, and_int_-2 in one thousand human breast tumors: correlation with steroid receptors.Eur. J. Cancer 28:697–700.
    PubMed Google Scholar
  42. R. Seshadri, C. S. L. Lee, R. Hui, K. McCaul, D. J. Horsfall, and R. L. Sutherland. Cyclin D1 amplification is not associated with poor prognosis in primary breast cancer. (submitted).
  43. H. Tsuda, S. Hirohashi, Y. Shimosato, T. Hirota, S. Tsugane, H. Yamamoto, N. Miyajima, K. Toyoshima, T. Yamamoto, J. Yokota, T. Yoshida, H. Sakamoto, M. Terada, and T. Sugimura (1989). Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units:_hst_-1/_int_-2 and c-_erb_B2/_ear_-1.Cancer Res. 49:3104–3108.
    PubMed Google Scholar
  44. A. Borg, H. Sigurdsson, G. M. Clark, M. Ferno, S. A. Fuqua, H. Olson, D. Kilander, and W. L. McGuire (1991). Association of_INT_2/HST coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis.Br. J. Cancer 63:136–142.
    PubMed Google Scholar
  45. E. Schuuring, E. Verhoeven, H. van Tinteren, J. L. Peterse, B. Nunnink, F. B. J. M. Thunnissen, P. Devilee, C. J. Cornelisse, M. J. van de Vijver, W. J. Mooi, and R. J. A. M. Michalides (1992). Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer.Cancer Res. 52:5229–5234.
    PubMed Google Scholar
  46. J. A. Henry, C. Hennessy, D. L. Levett, T. W. J. Lennard, B. R. Westley, and F. E. B. May (1993)._int_-2 amplification in breast cancer: association with decreased survival and relationship to amplification of c-_erb_B-2 and c-myc.Int. J. Cancer 53:774–780.
    PubMed Google Scholar
  47. E. M. J. J. Berns, J. A. Foekens, I. L. van Staveren, M. P. Look, W. L. J. van Putten, H. Portengen, M. Meijer-vanGelder, and J. G. M. Klijn. c-MYC gene amplification is preferable to amplification of_HER2/NEU_ or 11q13 regarding prognostic (and predictive) information: an analysis on 663 breast cancer patients. (submitted).
  48. K. Keyomarsi, N. O'Leary, G. Molnar, E. Lees, H. J. Fingert, and A. B. Pardee (1994). Cyclin E, a potential prognostic marker for breast cancer.Cancer Res. 54:380–385.
    PubMed Google Scholar
  49. T. K. Said and D. Medina (1995). Cell cyclins and cyclin dependent kinase activities in mouse mammary tumor development.Carcinogenesis 16:823–830.
    PubMed Google Scholar
  50. J. Lukas, J. Bartkova, M. Welcker, O. W. Petersen, G. Peters, M. Strauss, and J. Bartek (1995). Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types.Oncogene 10:2125–2134.
    PubMed Google Scholar
  51. A. Kamb (1995). Cell-cycle regulators and cancer.Trends Genet. 11:136–140.
    PubMed Google Scholar
  52. A. Okamoto, D. J. Demetrick, E. A. Spillare, K. Hagiwara, S. P. Hussian, W. P. Bennett, K. Forrester, B. Gerwin, M. Serrano, D. H. Beach, and C. C. Harris (1994). Mutations and altered expression of p16INK4 in human cancer.Proc. Natl. Acad. Sci. U.S.A. 91:11045–11049.
    PubMed Google Scholar
  53. A. Kamb, N. A. Gruis, J. Weaver-Feldhaus, Q. Liu, K. Harshman, S. V. Tavtigian, L. J. Old, E. Stockert, R. S. Day, B. Johnson, and M. H. Skolnick (1994). A cell cycle regulator potentially involved in genesis of many tumor types.Science 264:436–440.
    PubMed Google Scholar

Download references